Skip to main content
Figure 1 | BMC Infectious Diseases

Figure 1

From: Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir

Figure 1

Longitudinal evaluation of the percentage of change of different biomarkers from baseline by treatment groups. Percent of change from baseline calculated as 100 · [emean difference from baseline -1] in which mean difference from baseline is calculated on the natural log scale. P-value within arms reflecting whether the percent change from baseline is significantly different from 0: *P < 0.05, †P < 0.01, ‡P < 0.001. P-value derived from the comparison in percent change from baseline between the two treatment arms (abacavir vs. tenofovir): §P = 0.032. Comparisons were adjusted for age, sex, ART status at inclusion, viral load at baseline, lipodystrophy, Framingham score and hepatitis C virus co-infection status.

Back to article page